Effects and tolerability at irbesartan versus enalapril in patients with severe hypertension

被引：59

作者：

Larochelle, P

Flack, JM

Marbury, TC

Sareli, P

Krieger, EM

Reeves, RA

机构：

[1] MONTREAL GEN HOSP,HOTEL DIEU,MONTREAL,PQ H3G 1A4,CANADA

[2] WAKE FOREST UNIV,BOWMAN GRAY SCH MED,HYPERTENS CTR,WINSTON SALEM,NC

[3] ORLANDO CLIN RES CTR,ORLANDO,FL

[4] BARAGWANATH HOSP,CARDIOL RES CLIN,ZA-2013 JOHANNESBURG,SOUTH AFRICA

[5] UNIV HOSP,INST HEART,INST DO CORACAO,SAO PAULO,BRAZIL

[6] BRISTOL MYERS SQUIBB PHARMACEUT RES INST,PRINCETON,NJ 08543

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 1997年 / 80卷 / 12期

关键词：

D O I：

10.1016/S0002-9149(97)00784-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this double-blind, randomized study, an antihypertensive regimen based on irbesartan, an angiotensin II receptor antagonist, reduced systolic and diastolic blood pressure by 40/30 mm Hg at week 12 in patients with severe hypertension; this reduction was at least equivalent to that of a regimen using enalapril up to 40 mg. The irbesartan-based regimen had a better tolerability profile with fewer adverse events (55% vs 64%) and significantly less cough (2.5% vs 13.1%, p = 0.007).

引用

页码：1613 / &

页数：4

共 10 条

[1]

CAZAUBON C, 1993, J PHARMACOL EXP THER, V265, P826

[2] SAFETY AND TOLERABILITY OF LOSARTAN POTASSIUM, AND ANGIOTENSIN-II RECEPTOR ANTAGONIST, COMPARED WITH HYDROCHLOROTHIAZIDE, ATENOLOL, FELODIPINE ER, AND ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS FOR THE TREATMENT OF SYSTEMIC HYPERTENSION [J].